SCINAI Executives Buy 520 Million Shares in Zero‑Price Offer, Boosting Stakes Over 10 % in Low‑Cap Biotech
SCINAI insider buys signal confidence in a low‑cap biotech’s future—chairman and CEO acquire millions of shares, hinting at potential upside amid a steep decline.
- SCINAI IMMUNOTHERAPEUTICS LT
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read